Potentiation of estrogen receptor activation function 1 (AF-1) by Src/JNK through a serine 118-independent pathway

Molecular Endocrinology

Volumn 15, Issue 1, 2001, Pages 32-45

  Feng, Weijun ^a   Webb, Paul ^a   Nguyen, Phuong ^a   Liu, Xiaohong ^c   Li, Jiandong ^b   Karin, Michael ^c   Kushner, Peter J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN TYROSINE KINASE; RAF PROTEIN; SERINE; TAMOXIFEN;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; RECEPTOR INTRINSIC ACTIVITY;

EID: 0035134504     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.15.1.0590     Document Type: Article

References (87)

1. Transcriptional activation by oestrogen receptors
2. Antiestrogen-estrogen receptor interactions
3. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen
4. Effect of antagonists on DNA binding properties of the human estrogen receptor in vitro and in vivo
5. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
6. Nuclear receptor co-activators
7. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action
8. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
9. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
10. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors
11. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors
12. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors
13. The transcriptional coactivator p/CIP binds CBP and mediates nuclear-receptor function
14. AIB1, a steroid receptor coactivator amplifled in breast and ovarian cancer
15. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300
16. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2
17. TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1
18. Role of CBP/P300 in nuclear receptor signalling
19. p300 is a component of an estrogen receptor coactivator complex
20. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300
21. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
22. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein
23. Transcription factor-specific requirements for coactivators and their acetyltransferase functions
24. Estrogen receptor activation function 1 works by binding p160 coactivator proteins
25. A possible involvement of TIF1α and TIF1β in the epigenetic control of transcription by nuclear receptors
26. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways
27. A signature motif in transcriptional co-activators mediates binding to nuclear receptors
28. Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor
29. Nuclear receptor-binding sites of coactivators glucocorticoid receptor interacting protein 1 (GRIP1) and steroid receptor coactivator 1 (SRC-1): Multiple motifs with different binding specificities
30. The CBP co-activator is a histone acetyltransferase
31. The transcriptional coactivators p300 and CBP are histone acetyltransferases
32. Steroid receptor coactivator-1 is a histone acetyltransferase
33. Cross talk between peptide growth factor and estrogen receptor signaling systems
34. Peptide growth factor cross-talk with the estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol
35. Two separate mechanisms for ligand-independent activation of the estrogen receptor
36. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation
37. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
38. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase
39. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region
40. Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity
41. Purification and identification of p68 RNA helicase acting as a transcriptional coactivator specific for the activation function 1 of human estrogen receptor α
42. Targeting the EGF receptor in breast cancer treatment
43. EGF receptor expression, regulation, and function in breast cancer
44. Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research
45. HER-2/neu signal transduction in human breast and ovarian cancer
46. Expression of pp60c-src protein kinase in adult and fetal human tissue: High activities in some sarcomas and mammary carcinomas
47. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues
48. Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product
49. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis
50. Activation of the Src family of tyrosine kinases in mammary tumorigenesis
51. Regulation, substrates and functions of src
52. Src family protein tyrosine kinases: Cooperating with growth factor and adhesion signaling pathways
53. Cellular functions regulated by Src family kinases
54. v-src Induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor
55. L-selectin activates JNK via src-like tyrosine kinases and the small G-protein Rac
56. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs
57. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells
58. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
59. Cellular mechanisms which distinguish between hormone- and antihormone-activated estrogen receptor
60. The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties
61. Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element
62. Estradiol-binding mechanism and binding capacity of the human estrogen receptor is regulated by tyrosine phosphorylation
63. The role of estradiol receptor in the proliferative activity of vanadate on MCF-7 cells
64. Ligand-independent activation of the oestrogen receptor by mutation of a conserved tyrosine
65. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein
66. Function of estrogen receptor tyrosine 537 in hormone binding, DNA binding, and transactivation
67. Estradiol membrane binding sites on human breast cancer cell lines. Use of a fluorescent estradiol conjugate to demonstrate plasma membrane binding systems
68. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: Studies of ERα and ERβ expressed in Chinese hamster ovary cells
69. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo
70. Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2
71. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions
72. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation
73. Control of AP-1 activity by signal transduction cascades
74. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73
75. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain
76. Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation
77. Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain
78. c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions
79. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins
80. Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway
81. Potent inhibition of breast cancer cell lines by the isoflavonoid kievitone: Comparison with genistein
82. Effect of oestradiol and insulin on the proliferative pattern and on oestrogen and progesterone receptor contents in MCF-7 cells
83. Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells
84. The limits of the cellular capacity to mediate an estrogen response
85. Mutations in the conserved C-terminal sequence in thyroid hormone receptor dissociate hormone-dependent activation from interference with AP-1 activity
86. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
87. Transcriptional activators differ in their responses to overexpression of TATA-box-binding protein